Τόμος 19 (2005) – Τεύχος 1 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 19 (2005) – Issue 1 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

 

Title Malignant melanoma: a general overview
Authors Melpomeni Stoikidou¹, Maria Parava², Alexander Zisopoulos³, Helen Plessa, Despina Dessou and Fragiski Anthouli

1.      Department of Health Visiting, Faculty of Health and Caring Professions, Technological Educational Institution of Athens, Athens, Greece

2.     Peripheral Infirmary Terpyllou, General Hospital of Kilkis, Kilkis, Greece

3.     Peripheral Infirmary Vathis, General Hospital of Kilkis, Kilkis, Greece

4.     School of Business Administration and Economics, Technological Educational Institution of Athens, Athens, Greece

5.     General Department of Essential Medical Subjects, Faculty of Health and Caring Professions, Technological Educational Institution of Athens, Athens, Greece

Citation Stoikidou, M., Parava, M., Zisopoulos, A., Plessa, H., Dessou, D. et al.: Malignant melanoma: a general overview, Epitheorese Klin. Farmakol. Farmakokinet. 19(1): 3-9 (2005)
Publication Date Received for publication: 30 October 2004

 Accepted for publication: 9 January 2005

Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) 

pharmakonpress[at]pharmakonpress[.]gr

Keywords Malignant melanoma, epidemiological aspects, risk factors, pathogenesis, classification, treatment, prognosis.
Other Terms review article
Summary The incidence of cutaneous malignant melanoma, like the other non-melanocytic cancers, is still increasing In most fair skinned populations. The fashion of intermittent exposure to solar ultraviolet (UV) radiations is considered the main cause of this increase. In this review, epidemiology, risk factors for melanoma development, pathogenesis and clinical picture are discussed respectively, and treatment methods are analyzed carefully. Additionally, the importance of classification and of several factors determining tumor prognosis are also described.
References 1.       Vivier A., McKee P.H.: Clinical dermatology. Medical publications P.Ch. Paschalidis, Pp. 924-934, Αθήνα, 1997

2.       Desmond R.A., Soong S.: Epidemiology of malignant melanoma. Surg. Clin. North Amer. 83: 1-29 (2003)

3.       Geller A.C., Annas G.D.: Epidemiology of melanoma and nonmelanoma skin cancer. Seminar-Oncology-Nursing. Pp. 2-11, 2003

4.       Lee J.E.: Factors associated with melanoma incidence and prognosis. Semin. Surg. Oncol. 12: 379-385 (1996)

5.       Wang C.Y., Brodland D.G., Su W.P.: Skin cancers associated with acquired immunodeficiency syndrome. Mayo Clin. Proc. 70: 766-72 (1995)

6.       Rhodes A.R., Weinstock M.A., Fitzpatrick T.B., et al.: Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 258: 3146- 3154 (1987)

7.       Albert L.S., Rhodes A.R., Sober A.J.: Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives. J. Am. Acad. Dermatol. 22: 69-75 (1990)

8.       Armstrong B.K.: Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? J. Dermatol. Surg. Oncol. 14: 835-849 (1988)

9.       Marks R.: An overview of skin cancers. Incidence and causation. Cancer 75: 607-612 (1995)

10.     Rodenas J. et al.: Sun exposure, pigmentary traits and risk of cutaneous malignant melanoma. Cancer-causes-control 7: 275-283 (1996)

11.      Staurianeas N.G., Agelakopoulos Ch.: Malignant melanoma. Modern Dermatological Oncology. Medical publications, P.Ch. Paschalidis, Pp. 129-156, Αθήνα, 2001

12.     Bito T., Oka M.: UV-induced skin damage. Toxicology 189(1-2): 21-39 (2003)

13.     Stratigos A.I: The molecular basis of skin photocarcinogenesis, Iatriki 77: 432-446 (2000)

14.     Kapetanakis l.: Illustrated dermatology. Scientific publications Parisianos, Pp. 217-220, Αθήνα, 1987

15.     Zoumpourlis B., Solakidi S., Papathoma A., Papaevangeliou D.: Alterations in signal transduction pathways implicated in tumor progression during multistage mouse skin carcinogenesis. Carcinogenesis 24: 1159-1162 (2003)

16.     Keller, Schmidt, Peipkorn: Expression of the tumor suppressor gene product p16INK4 in benign and malignant Melanocytic lesions. J. Invest. Dermatol. 110: 932- 938 (1998)

17.     Polyzos A., Papadopoulos O.: Development in surgical classification and preventive melanoma treatment, Iatriki 73: 420-424(1998)

18.     Krag S., Harlow S., Weaver D., Ashikaga T.: Techniques of sentinel node resection in melanoma and breast cancer: probe-guided surgery and lymphatic mapping. Eur. J. Surg. Oncol. 24: 89-93(1998)

18.     Spanos P.: General Surgery. Volume 1, pp. 260-265, University Studio Press, Thessaloniki, 2001

19.     Brown C.K., Kirkwood J.M.: Medical management of melanoma. Surg. CHn. North Amer. 82. 283-322 (2003)

20.    Geraghty P., Johnson T, Sondak V., Chang A.: Surgical therapy of primary cutaneous Melanoma. Semin. Surg. Oncol. 12 386-393 (1996)

21.     Johnson T.M, Smith J.W., Nelson B.R, Chang A.: Current therapy for cutaneous melanoma. J. Am. Acad. Dermatol. 32: 689-707 (1995)

22.     Veronesi U., Cascinelli N.: Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch. Surg. 126: 4384-4341 (1991)

23.     Kian A.K., Geara F.B., Byers R.M., Peters L.J.: Radiotherapy for Melanoma. Cutaneous Melanoma, Quality Medical Publishing, pp: 384-403, St Louis, 1998

24.     Gennatas K.S.: Melanoma immunotherapy. Modern dermatological oncology. Medical Publications, P.Ch. Paschalidis, pp. 161-163, Αθήνα, 2001

25.     Kirkwood J.M., Strawderman W.H., Ernstoff M.S., et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma. J. Clin. Oncol. 14: 7-17 (1996)

26.     Rosenberg S.A, Yang J.C, Topalian S.L., et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913 (1994)

27.     Zettersten E., Shaikh L., Ramirez R., Sabet M.: Prognostic factors in primary cutaneous melanoma. Surg. Clin. North Amer. 83: 61-75 (2003)

28.    Schaffer J., Rigel D., Kopf A., Bologna J.: Cutaneous melanoma – Past, present, and future. J. Am, Acad. Dermatol. 51: S65-S69 (2004)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2005– ANNUAL SUBSCRIPTION 2005
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

Bookmark the permalink.

Comments are closed.